Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/expTCduTtWCjaOchCidncVCicNyaLD
| Today's Top Story |  |  | | | Health Care & Policy | | | | - More evidence backs immunotherapies' use against cancer
Additional evidence was presented by researchers Saturday supporting the effectiveness of the use of drugs to mobilize the immune system in fighting tumors. Bristol-Myers Squibb's candidate drug nivolumab helped melanoma patients live an average of almost 17 months in a study, while another trial showed that the risk of death among advanced melanoma patients was reduced by adding Sanofi drug Leukine to Bristol's Yervoy. Immunotherapy drugs are intended to trigger the immune system to kill cancer cells. The Wall Street Journal/Dow Jones Newswires (6/1)       - Merck's lambrolizumab shows promise in advanced-melanoma trial
Merck & Co.'s experimental drug lambrolizumab shrank tumors in 38% of advanced-melanoma patients after 12 weeks of treatment during an early-stage trial. Based on the results of the study, Merck plans to advance the drug into a late-stage trial, which could begin next quarter. Reuters (6/2) | Company & Financial News | | | | - Eurofins boosts genomics business with Entelechon buy
Eurofins Scientific's genomic unit Eurofins MWG Operon purchased Entelechon, a gene synthesis firm based in Germany, for an undisclosed amount. Eurofins MWG has begun integrating Entelechon into its gene synthesis business. "Entelechon is an excellent strategic fit with Eurofins MWG Operon's genomic service offering and their competence on gene synthesis services and synthetic biology complements our DNA synthesis and sequencing units," said Bruno Poddevin of Eurofins MWG Operon. GenomeWeb Daily News (free registration) (6/3) | Global Developments | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Swiss firm in talks with potential partners for biofuel project
Switzerland-based Clariant is negotiating with potential partners in an advanced ethanol project that would take advantage of enzyme technology gained in its $2.5 billion acquisition of Sued-Chemie. Clariant is seeking a partner to develop a next-generation biofuel facility with a 150,000-ton capacity, said Markus Rarbach, the company's head of biofuels and derivatives unit. The company expects U.S. demand for homegrown fuel and Europe's push for biofuel will open a niche for its product. Bloomberg (6/3) | News from BIO | | | | - April 2013 BIO therapeutic newsletters
The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access our April 2013 Therapeutic Newsletters. Should you have any comments or questions, please contact Charles Crain.
| SmartQuote | | | |  | To be capable of steady friendship or lasting love, are the two greatest proofs, not only of goodness of heart, but of strength of mind."
--William Hazlitt,
British writer and philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, June 03, 2013
- Friday, May 31, 2013
- Thursday, May 30, 2013
- Wednesday, May 29, 2013
- Tuesday, May 28, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment